Eilmeldung

UKMet Office Expands Extreme Heat Warning for UK, Record Highs Expected GLOBALUS and Iran Officials Meet in Switzerland for Direct Talks on Ending War INTLLA Mayor Declares State of Emergency Over Cold-Storage Facility Fire INIran's Tasnim Reports Strait of Hormuz Closure Linked to Lebanon Ceasefire, Oil Waivers USMan Dies After Falling During Concert at Madison Square Garden GLOBALBrendon McCullum Confirms Ben Stokes to Return as England Captain for Third Test INA Decade Since Brexit: Economic Toll, Shifting Opinions, and Political Fallout UKWest Indies edge Sri Lanka in T20 World Cup thriller CRYPTO-ENNew Framework Explains AI Psychosis Reports, Linking Chatbot Behavior to Delusions INChina's DF-17 Hypersonic Missile Launch Footage Aired by CCTV UKMet Office Expands Extreme Heat Warning for UK, Record Highs Expected GLOBALUS and Iran Officials Meet in Switzerland for Direct Talks on Ending War INTLLA Mayor Declares State of Emergency Over Cold-Storage Facility Fire INIran's Tasnim Reports Strait of Hormuz Closure Linked to Lebanon Ceasefire, Oil Waivers USMan Dies After Falling During Concert at Madison Square Garden GLOBALBrendon McCullum Confirms Ben Stokes to Return as England Captain for Third Test INA Decade Since Brexit: Economic Toll, Shifting Opinions, and Political Fallout UKWest Indies edge Sri Lanka in T20 World Cup thriller CRYPTO-ENNew Framework Explains AI Psychosis Reports, Linking Chatbot Behavior to Delusions INChina's DF-17 Hypersonic Missile Launch Footage Aired by CCTV

estudo de fase 3

Stabil3 Meldungen1 QuellenZuletzt aktualisiert: 11.06.2026

Verwandte ThemenAnvisa survodutide Boehringer Ingelheim liver fat MASLD MASH obesity diabetes

Neueste Meldungen

Boehringer Ingelheim's experimental drug shows promise in reducing liver fat

Gesundheit·11.06.2026KI-Zusammenfassung

Boehringer Ingelheim's experimental drug shows promise in reducing liver fat

Boehringer Ingelheim's experimental drug, survodutide, has shown significant potential in reducing liver fat accumulation, a condition known as MASLD/MASH. Presented at the American Diabetes Association (ADA) annual meeting, the drug targets both weight loss and metabolic health, offering a new approach beyond traditional obesity treatments.

Anvisa aprova novo medicamento para Parkinson avançado no Brasil

25.05.2026KI-Zusammenfassung

Anvisa aprova novo medicamento para Parkinson avançado no Brasil

A Anvisa aprovou Vyalev, um novo tratamento para Parkinson avançado que combina foscarbidopa e foslevodopa em infusão subcutânea contínua. A terapia visa manter níveis estáveis da medicação, reduzindo oscilações motoras e oferecendo alternativa a pacientes que não respondem a tratamentos orais ou não podem fazer cirurgia.

Anvisa aprova rimegepanto, novo medicamento para enxaqueca da Pfizer

25.05.2026KI-Zusammenfassung

Anvisa aprova rimegepanto, novo medicamento para enxaqueca da Pfizer

A Anvisa aprovou o rimegepanto, medicamento da Pfizer para enxaqueca, em comprimidos orodispersíveis. O fármaco, que bloqueia o CGRP, mostrou eficácia em estudos, aliviando dor e sintomas associados.